CIFoundry
Back to Catalog
Pathology
FDA Cleared

Ibex Galen (Ibex Prostate Detect)

Save to shortlist
Ibex Medical Analytics Ltd. (Tel Aviv, Israel)2016

Last reviewed Oct 31, 2026 against the sources listed on this page · How we review

At a glance

Ibex Medical Analytics' Galen platform is a clinical-grade AI cancer diagnostics suite for prostate, breast, and gastric biopsies that acts as an AI 'second read' to flag suspicious foci and…

FDA:
510(k) K241232
Epic:
Not on record
Named users:
1 named in public reports
Published study:
Not on record

Description

Ibex Medical Analytics' Galen platform is a clinical-grade AI cancer diagnostics suite for prostate, breast, and gastric biopsies that acts as an AI 'second read' to flag suspicious foci and reduce missed cancers. Ibex Prostate Detect received FDA 510(k) clearance in February 2025, supported by validation showing a 99.6% positive predictive value and detection of 13% of cancers initially missed by pathologists. The platform is deployed in routine clinical practice across hospital networks and reference laboratories.

digital pathologycancer detectionFDA 510(k)prostate cancerbreast cancersecond readclinical AI

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is Ibex Galen (Ibex Prostate Detect) FDA cleared?
The public FDA database has one record that our team matched to Ibex Galen (Ibex Prostate Detect). The most recent is 510(k) K241232 (Galen™ Second Read™), decided Jan 2025. Check that the cleared use matches how you plan to use it.FDA record K241232
Which health systems use Ibex Galen (Ibex Prostate Detect)?
Linked public reports name one organization: Alverno Laboratories. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.Alverno Laboratories (Northwest Indiana Business Magazine)

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Not assessed

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

6 organizations

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

Reported by the developer

Alverno Laboratories (30+ hospital labs, IL/IN)Cambridge University Hospitals (UK)NHS WalesMedipath (France)PathLAKE NHS Trusts (UK)

Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.

Get weekly updates for Pathology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website

FDA database records

  • K241232 · 510(k) · Jan 2025
    Galen™ Second Read™

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (3)Show

Dated events on this listing's public record, newest first.

  1. Sep 13, 2026

    Added to CIFoundry

  2. Jan 24, 2025

    FDA 510(k) K241232 decision datesource

  3. May 18, 2023

    News report names Alverno Laboratories as a user (Northwest Indiana Business Magazine)source

Developer

Ibex Medical Analytics

Ibex Medical Analytics Ltd. (Tel Aviv, Israel)

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.